TLPPF (Telix Pharmaceuticals) Total Equity: $415.4 Mil (As of Dec. 2025)


TLPPF Telix Pharmaceuticals Ltd TLPPF
66 GF Score
Price $10.00
GF Value $27.87
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Telix Pharmaceuticals Total Equity?

Telix Pharmaceuticals TLPPF -0.40% 66 Total Equity is $415.4 Mil as of Dec. 2025. GuruFocus rates TLPPF with a GF Score™ of 66/100 and a GF Value™ of $27.87 (Possible Value Trap). The stock has 6 warning signs investors should review.

Telix Pharmaceuticals's total equity for the quarter that ended in Dec. 2025 was $415.4 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Telix Pharmaceuticals Total Equity Historical Data

* Premium members only.

The historical data trend for Telix Pharmaceuticals's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telix Pharmaceuticals Total Equity Chart

Telix Pharmaceuticals Annual Data
Trend Sep00 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.56 54.43 102.65 352.94 415.38

Telix Pharmaceuticals Semi-Annual Data
Sep00 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 102.65 270.02 352.94 421.94 415.38
TLPPF
66GF Score
Telix Pharmaceuticals Ltd TLPPF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Telix Pharmaceuticals Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Telix Pharmaceuticals's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1163.986-748.61
=415.4

Telix Pharmaceuticals's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1163.986-748.61
=415.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $415.4 Mil mean?
Telix Pharmaceuticals (TLPPF) has a Total Equity of $415.4 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Telix Pharmaceuticals and its competitors.
Is Telix Pharmaceuticals' Total Equity too high?
Telix Pharmaceuticals' current Total Equity is $415.4 Mil. Overall, Telix Pharmaceuticals has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Total Equity compare to VRTX and REGN?
Telix Pharmaceuticals' Total Equity of $415.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Telix Pharmaceuticals and its competitors. Telix Pharmaceuticals's current Total Equity is $415.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLPPF) is currently considered Possible Value Trap. The stock's GF Value™ is $27.87, compared to a current price of $10.00 — trading 64.1% below its estimated fair value. The current Total Equity is $415.4 Mil. Telix Pharmaceuticals' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Telix Pharmaceuticals (TLPPF), the current Total Equity is $415.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Telix Pharmaceuticals (TLPPF) Overvalued in 2026?

Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued. The current stock price of $10.00 is trading 64.1% below its estimated GF Value™ of $27.87. GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.

Key valuation signals for TLPPF:

  • Total Equity: $415.4 Mil
  • GF Value™: $27.87 vs. price of $10.00 (64.1% below fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the TLPPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Telix Pharmaceuticals Business Description

Address 55 Flemington Road, Level 4, North Melbourne, Melbourne, VIC, AUS, 3051
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
66GF Score

Get the complete analysis for TLPPF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.00
Price
$27.87
GF Value